Defective proliferative potential of MSCs from pediatric myelodysplastic syndrome patients is associated with cell senescence.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  International Journal of Clinical and Experimental Pathology

• Publication date

  2015-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 26722501PMCID PMC4680446
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Impaired Proliferative Potential of Bone Marrow Mesenchymal Stromal Cells in Patients with Myelodysplastic Syndromes Is Associated with Abnormal WNT Signaling Pathway

  2014cited by this paper
• Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells

  2013cited by this paper
• The Different Immunoregulatory Functions on Dendritic Cells between Mesenchymal Stem Cells Derived from Bone Marrow of Patients with Low-Risk or High-Risk Myelodysplastic Syndromes

  2013cited by this paper
• Functional characteristics of mesenchymal stem cells derived from bone marrow of patients with myelodysplastic syndromes.

  2012cited by this paper
• Myelodysplastic syndromes: revisiting the role of the bone marrow microenvironment in disease pathogenesis

  2012cited by this paper
• Advances in the prognostication and management of advanced MDS in children

  2011cited by this paper
• Importance of Sox2 in maintenance of cell proliferation and multipotency of mesenchymal stem cells in low‐density culture

  2011cited by this paper
• Focal adhesion protein abnormalities in myelodysplastic mesenchymal stromal cells.

  2011cited by this paper
• Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts.

  2011cited by this paper
• Reserves, Functional, Immunoregulatory, and Cytogenetic Properties of Bone Marrow Mesenchymal Stem Cells in Patients with Myelodysplastic Syndromes

  2010influential reference
• Myelodysplastic syndromes.

  2009cited by this paper
• Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q− syndrome

  2009cited by this paper
• Functional analysis of myelodysplastic syndromes-derived mesenchymal stem cells.

  2008cited by this paper
• Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies.

  2008cited by this paper
• Myelodysplastic syndromes: molecular pathogenesis and genomic changes

  2008cited by this paper
• Age‐related intrinsic changes in human bone‐marrow‐derived mesenchymal stem cells and their differentiation to osteoblasts

  2008cited by this paper
• Myelodysplastic syndromes in children: a critical review of issues in the diagnosis and classification of 887 cases from 13 published series.

  2007cited by this paper
• Aging of mesenchymal stem cell in vitro

  2006cited by this paper
• Aging of mesenchymal stem cells.

  2006cited by this paper
• Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.

  2006cited by this paper
• Mesenchymal stem cells in myelodysplastic syndromes: phenotypic and cytogenetic characterization.

  2005cited by this paper
• The International Prognostic Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML)

  2004cited by this paper
• A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases

  2003cited by this paper
• Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells.

  2003cited by this paper
• Functional disturbance of marrow stromal microenvironment in the myelodysplastic syndromes

  2002cited by this paper

• Cell surface markers for mesenchymal stem cells related to the skeletal system: A scoping review

  2023cites this paper
• Senescent Mesenchymal Stem Cells in Myelodysplastic Syndrome: Functional Alterations, Molecular Mechanisms, and Therapeutic Strategies

  2021cites this paper
• In search of elixir: Pharmacological agents against stem cell senescence

  2021cites this paper
• Cellular senescence induced by S100A9 in mesenchymal stromal cells through NLRP3 inflammasome activation

  2019cites this paper
• Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival

  2018cites this paper
• Characterization of the pulmonary and systemic immune response in relation with lung stem cells in patients with COPD

  2017cites this paper
• Myeloid malignancies and the microenvironment.

  2017cites this paper
• Abnormal mRNA Expression Levels of Telomere-Binding Proteins Represent Biomarkers in Myelodysplastic Syndromes: A Case-Control Study

  2017cites this paper
• Synergistic effect of 1α,25-dihydroxyvitamin D3 and 17β-estradiol on osteoblast differentiation of pediatric MSCs.

  2017cites this paper
• The microenvironment in myelodysplastic syndromes: Niche-mediated disease initiation and progression.

  2017cites this paper
• Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis—Masters of Survival and Clonality?

  2016cites this paper